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Background: Patients with acute leukemia experience a substantial symptom burden and are at risk of developing
infections throughout the course of repeated cycles of intensive chemotherapy. Physical activity in recent years has
been a strategy for rehabilitation in cancer patients to remedy disease and treatment related symptoms and side
effects. To date, there are no clinical practice exercise guidelines for patients with acute leukemia undergoing
induction and consolidation chemotherapy. A randomized controlled trial is needed to determine if patients with
acute leukemia can benefit by a structured and supervised counseling and exercise program.
Methods/design: This paper presents the study protocol: Patient Activation through Counseling and
Exercise – Acute Leukemia (PACE-AL) trial, a two center, randomized controlled trial of 70 patients with acute
leukemia (35 patients/study arm) following induction chemotherapy in the outpatient setting. Eligible patients will
be randomized to usual care or to the 12 week exercise and counseling program. The intervention includes 3
hours + 30 minutes per week of supervised and structured aerobic training (moderate to high intensity 70 - 80%)
on an ergometer cycle, strength exercises using hand weights and relaxation exercise. Individual health counseling
sessions include a self directed home walk program with a step counter. The primary endpoint is functional
performance/exercise capacity (6 minute walk distance). The secondary endpoints are submaximal VO2 max test, sit
to stand and bicep curl test, physical activity levels, patient reported outcomes (quality of life, anxiety and
depression, symptom prevalence, intensity and interference). Evaluation of clinical outcomes will be explored
including incidence of infection, hospitalization days, body mass index, time to recurrence and survival. Qualitative
exploration of patients’ health behavior and experiences.
Discussion: PACE-AL will provide evidence of the effect of exercise and health promotion counseling on functional
and physical capacity, the symptom burden and quality of life in patients with acute leukemia during out patient
management. The results will inform clinical practice exercise guidelines and rehabilitation programs for patients
undergoing treatment for acute leukemia. Optimizing the treatment and care pathway may ease the transition for
patients from illness to the resumption of everyday activities.
Trial registration: ClinicalTrials.gov Identifier: NCT01404520.
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Acute leukemia is a life threatening hematological malig-
nancy, representing one percent of all cancers diagnosed
annually in Denmark, which approximates to 200 new
cases of acute myeloid leukemia (AML) and 50 acute
lymphatic leukemia (ALL) cases in adults yearly (cancer.
dk). The five-year international survival for AML is 40%
for adult patients (<60 yrs) receiving curative intended
treatment, and for ALL 50% (18–45 yr) and 10-30%
(>45 yr) [1,2]. The WHO performance status score of pa-
tients with AML at the time of diagnosis has been shown
to have prognostic importance [3]. The primary goal of
treatment for acute leukemia is to rapidly achieve complete
remission attained by the initial intensive chemotherapy
regimen (induction), followed by repeated cycles of inten-
sive chemotherapy (consolidation) and if indicated, an allo-
geneic stem cell transplantation. Each chemotherapy cycle
is followed by severe neutropenia, thrombocytopenia and
anemia, with an increased risk of serious infections, mainly
septicemia and pneumonia [4]. Deterioration of nutritional
status and quality of life (QOL) is reported after induction
treatment [5]. Patients report a substantial symptom bur-
den including lack of energy, shortness of breath, weak-
ness, comprised physical functioning, difficulty sleeping,
pain, nausea, emesis, diarrhea, weight loss, anxiety and dis-
tress [5-7]. Further, clinically significant depression can be
precipitated or exacerbated by a diagnosis of acute
leukemia [8]. Multiple symptoms have been found to have
a deteriorating effect on QOL in patients with hematologic
malignancy [9-11].
Over the past 15 years, patient safety aspects and
prolonged hospitalization have been challenged by
homecare interventions and outpatient management
programs triggered by the prospect of improving QOL
by reducing hospital admissions [12]. Implementation of
outpatient programs for patients with acute leukemia
have enabled patients to be discharged to their homes
while receiving mandatory antibiotic prophylaxis during
neutropenic phases [13,14]. For the patient, this requires
frequent, lengthy, long term and supervised visits for
treatment and follow-up care, ongoing transfusion
support and close monitoring for complications includ-
ing serious infections. Pharmacological strategies, as
antibiotic prophylaxis, antiemetics etc. are frequently
prescribed to improve tolerance to the planned chemo-
therapy treatment, and now physical activity in recent
years has been used as a strategy for rehabilitation in
cancer patients to remedy disease and treatment related
symptoms and side effects. Evidence suggests that
activation of cancer patients can result in healthy behav-
iors i.e. physical activity, and lead to better health-
related outcomes and self care management [15,16]. In
addition, tailored counseling sessions have been shown
to improve functioning, clinical outcomes and reducehospitalization [17]. Feasibility, safety and beneficial ef-
fects of low to high intensity exercise and psychosocial
interventions have been found in cancer patients with
the majority being breast cancer, and to a much lesser
extent in colon, prostate, lung and hematological malig-
nancies [18-21]. However, the complex clinical situation
seen in acute leukemia has predominantly excluded
patients from participating in exercise interventions.
Furthermore, present clinical care practice does not in-
corporate health counseling and physical exercise during
treatment for acute leukemia which leaves this particular
patient group understudied and under recruited in
existing exercise-based rehabilitation programs. In a re-
cent review of exercise in hematological cancer survivors
[22], only three small scale studies comprise patients
with acute leukemia [23-25], and one pilot study with a
mixed population of acute leukemia and lymphoma [26],
all during hospitalization while undergoing the induction
phase of chemotherapy treatment. These limited find-
ings, indicate feasibility, safety and preliminary physio-
logical and psychosocial benefits from exercise in
patients during induction treatment for acute leukemia.
In our recently published pilot study (n = 20), we inter-
vened in the outpatient management setting by building
a bridge between the hospital and daily life activities of
patients with acute leukemia by addressing the
challenges associated with maintaining muscle, cardio-
vascular and emotional and general health during
chemotherapy treatment [9]. This 6 week supervised and
structured exercise and health counseling intervention
proved feasible, safe and well tolerated with physical,
functional, psychosocial and symptom benefits in a small
sample of patients with acute leukemia undergoing in-
tensive chemotherapy. However, no recommendation for
exercise can be issued specifically for acute leukemia pa-
tients undergoing induction and consolidation treatment
during hospitalization and outpatient treatment and care
[9,22].
This protocol paper presents our current randomized
trial (PACE-AL) that aims to investigate the effect of a
12 week structured and supervised multimodal program
of physical exercise and health counselling in patients
with acute leukemia undergoing consolidation treatment
during outpatient treatment and care. It is hypothesized
that the intervention can minimize the loss of physical
and functional capacity, reduce the symptom burden,
improve psychosocial wellbeing and health related QOL.
To our best knowledge, this is a first time study that ex-
amines a multimodal intervention of health counseling
and exercise in patients with acute leukemia, initiated
early in the treatment trajectory prior to consolidation
treatment and conducted over a 12 week period. The
long term effect of the intervention will be investigated
at 6 and 12 month follow-up.
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Participants and setting
This randomized controlled trial is a prospective, two
group trial of a 12 week exercise and health counsel-
ing intervention in patients with newly diagnosed
acute leukemia during the course of consolidation
treatment in the outpatient clinic. 70 patients will be
consecutively recruited and randomized by the re-
search investigator and/or the nurse specialists from
the Department of Hematology at two Copenhagen
University hospitals: The University Hospital of
Copenhagen, Rigshospitalet (RH) and Herlev Hospital
(HH). Patients ≥ 18 years newly diagnosed with acute
leukemia are eligible for the study upon completion
of their initial induction chemotherapy with a docu-
mented complete remission (CR) status, able to read














Figure 1 CONSORT diagram of patient recruitment and flow.informed written consent. The exclusion criteria are
recent symptoms of cardiovascular, neurological or
muscular disease, abnormal electrocardiogram and
uncontrolled high blood pressure.
Study and recruitment procedures
The study flow is presented in Figure 1. Potential partici-
pants will be identified and screened for eligibility by the
research investigator and/or clinical nurse specialist by
weekly reviews of patient admissions and their status
through medical record review and consultation with
the nursing and medical staff at the Departments of
Hematology, RH and HH. If eligible, the patients will be
approached once the initial induction chemotherapy
treatment is completed and complete remission (CR) is
achieved. The patients will be provided with verbal
and written information regarding the study andCentre RH
Eligible patients (n=35)
Randomized 
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Once written consent is obtained, the patients are im-
mediately scheduled for their baseline tests, which in-
clude four physical/exercise tests and asked to complete
patient reported outcome questionnaires (PRO). Baseline
tests and assessments will be repeated at 6 weeks and at
completion of the intervention period (12 weeks).
Selected participants (purposive sampling strategy) will
be interviewed at 12 weeks by the research investigator
(n = 25). Further, PRO tests will be repeated at 6 and 12
months. Three brief PRO pertaining to symptom assess-
ment and physical activity levels will be repeated once
weekly throughout the duration of the study period. To
strengthen internal validity, the procedures for tests/as-
sessments will be conducted under the same or similar
conditions at all three test points at both hospitals
(HH and RH). The study personnel and blinded out-
come assessors will conduct tests during the morning
hours (between 9 am-12 noon), utilize the same test
equipment and conduct the tests/assessments in a spe-
cific order.
Randomization and group allocation
After baseline testing, patients will be randomized to
one of two trial arms (intervention or control) using the
computerized Clinical Trial Management System
(CITMAS/HITMAS) [27] and stratified for age (<45 and
>45 years), gender, and treatment facility (RH and HH).
This is to ensure that the randomized groups are similar
at baseline. A block design with allocation weight of 1:1
will be used to generate treatment allocation. Random-
ized patients will remain in the same group for the en-
tire duration of the intervention.
Blinding
Blinding the participants or the investigators to alloca-
tion group will not be possible, however the outcome as-
sessors and the trials statistician will be blinded to the
participants study allocation. The trials statistician will
have access to unblinded data, but will prepare results
without knowledge of allocation to randomization
coding.
Trial arm 1 (intervention protocol and general
considerations)
The intervention program - exercise and counseling
(Tables 1 and 2) was designed using principles for exer-
cise suggested by the American College of Sports Medi-
cine (ACSM) [28] and a literature review on physical
activity and hematological cancer survivorship [22]. The
counseling sessions and the daily guidance and motiv-
ation are theoretically based on the social cognitive
model of health promotion [29], theory of planned be-
haviour [30] and motivational interviewing (MI)methods and principles [31-34]. The intervention is a
supervised hospital-based program that takes place at
designated training locations at two hematology out-
patient departments (RH,HH). Each session is designed
to last 1hour ±10 min., 3 days weekly during the patients
out-patient visit between 10 am and 12 noon beginning
the first day of ambulatory care and carried out for 12
weeks. Patients who are intermittently hospitalized due
to infection or other complications during the study
period will be offered the intervention in their hospital
room and when possible, the patient will be asked to
meet at the projects designated training areas. Consecu-
tive inclusion will enable training in small groups be-
tween 2 and 4 participants.
Intervention: pre-screening and safety precautions
The research investigator and/or the study’s clinical
nurse specialists and physiotherapists will pre-screen the
patients and supervise all sessions. If one or more of the
following criteria are present prior to the intervention,
the session will be either postponed or modified on that
specific day; diastolic blood pressure < 45 or > 95 mmHg,
pulse at rest > 100/min, signs of infection (temp > 38°C);
respiration frequency at rest > 20/min and signs of
bleeding (petechiae, nose bleeds, bruises). The units’
transfusion policy is for thrombocytopenia, platelets
< 15 × 109/l and for anemia, hemoglobin < 7.5 - 9 g/dl.
The patients will be continuously monitored with a
digital heart rate monitor (Polar Model) and observed
for adverse reactions/events (see Monitoring Adverse
Events).
The supervised exercise component of the intervention
comprises stationary cycling, and will be initiated for a
period of 20-25 min for each session. A minimum of six
work intervals are integrated to enable cardiovascular ef-
fect while ensuring safety and therefore aims to reach
but not exceed 80% of the maximal heart rate calculated
by ACSM formula (206.9 - (0.67 × age) + 75/80%) [35].
The subjective intensity of effort is evaluated by the Borg
Rate of Perceived Exertion scale (RPE), a visual analogue
scale ranging from 6 (light effort) to 20 (maximal exer-
tion) [36]. Intensity effort will strive to be between 15-17
(hard to very hard). The metabolic equivalent intensity
level (METS) is calculated for each physical activity
component [37]. The main goal of aerobic progression is
to gradually increase exercise intensity and duration. Six
dynamic and resistance exercises using free hand weights
will be carried out including bicep curl, shoulder press,
squat, lunge, push-ups, and one core exercise for ab-
dominal and back muscles. Exercises will be performed
in 2 sets of 12 repetitions, and hand weights will be ad-
justed to enable 2 sets and up to 12 repetitions. Progres-
sion aims to increase weight. The exercises will be
followed by relaxation training while lying supine (or
Table 1 The intervention program - exercise and health promotion counseling
PHYSICAL ACTIVITY COUNSELING
Physical Training Relaxation Training Diet Guidance and motivation Health counseling
Supervised (out-patient facility at hospital)
Stationary cycling Relaxation and breathing





Instruction and guidance in exercising,
usage of step counter and walking
program, short and long term motivation
and symptom management
Focus:
Moderate to very hard intensity 1) Screening
2) Health behavior




Interval training RPE 6-9 3) Social/employment
RPE 15-17 MET 2.5
MET 5.5 - 8 Protein: 16-19 g. GOAL SETTING
Carbohyd: 1400-1900 kj.
Dynamic and resistance training Individual Individual
Moderate to hard
2 sets, 12 reps
RPE 14-16
MET 5.5
3 days/week 3 sessions 30-60 min.
Not supervised (home, outdoors, hospital corridor etc.)


















Table 2 The weekly intervention program - exercise and health promotion counseling
WEEKLY PROGRAM 12 wks., 3 days/wk., 3-4 hours/wk. and daily walking
Monday Tuesday Wednesday Thursday Friday
Training program incl. relaxation (1 hr.) Training program incl. relaxation (1 hr.) Training program incl. relaxation (1 hr.)
Protein snack Protein snack Protein snack
Guidance and motivation Guidance and motivation Guidance and motivation
step counter step counter step counter
Week 1 Week 2 - 11 Week 12
Walk program with step counter Walk program with step counter Walk program with step counter
Establish habitual level Maintenance or progression Maintenance or progression
Week 6
(1) Health counseling (2) Health counseling (3) Health counseling
(30-60 min) (30-60 min) (30-60 min)
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[38-40]. At completion of each training session, the pa-
tients will consume a single or combined protein/carbo-
hydrate supplement (16-19 g. protein and 1600–2000 kj
carbohydrate) within 30 minutes of exercise to speed re-
covery by repairing and rebuilding muscle tissue [41,42].
Training sessions will be accompanied by guidance and
motivation by the research physiotherapists and clinical
nurse specialists with special focus on topics related to
the exercise program, short and long term motivation
and symptom management [29-34].
Counseling will be conducted three times for 30-60
min. at baseline, six and twelve weeks. Health promotion
counseling sessions are schematized and carried out by
the research investigator and/or clinical nurse specialists
through a circular process of pre-contemplation, con-
templation, preparation, action and maintenance [43].
The main principle of health counseling is to create a
partnership with the patient to improve adherence to
the intervention during the study period and to motivate
towards positive health behavior, including maintaining
or increasing physical activity during and beyond the su-
pervised exercise sessions, and also after completion of
the program. MI is a behavioral change strategy that as-
sumes the patient possesses inherent resources and mo-
tivation that may be enhanced through the patient’s own
expression of goals [29-34]. Each counseling session is
therefore goal oriented and offers guidance in aspects of
managing treatment-related symptoms, including symp-
toms of stress and anxiety, and issues related to diet,
smoking cessation, alcohol consumption, sleep, social
and daily life function and physical activity.
At the start of the program, the participants will re-
ceive a step counter (Omron Walking Style Pro) with
the motivational purpose of physical and behavioral
awareness and activation [44]. The patients will be fitted
with the step counter by the study physiotherapists and
instructed to wear the step counter during waking hours.Results from the step counter will be electronically
transferred to a laptop computer once a week for the
purpose of reviewing with each patient the number of
daily total steps and aerobic steps achieved during the
previous week, which will result in the patient express-
ing physical activity and walking goals for the following
week.
Trial arm 2 (control group)
The control group receives standard care and treatment
that does not include supervised physical activity and/or
health promotion counseling at the departments. Pa-
tients in both the intervention and control groups will
receive usual care and treatment, and are not restricted
from participating in other physical activity during the
study period.
Study endpoints and assessments
Outcome measures will be assessed at three time points,
baseline, six and twelve weeks with a 6 and 12 month
follow up. Table 3 outlines the study assessment sched-
ule. Demographic, performance status (WHO) and med-
ical data will be collected by journal review and
questionnaire. Assessments will be carried out between
9:00 am and 12:00 noon by the project outcome asses-
sors at their respective hospitals. Patients will be
instructed on proper technique for the tests, and will be
advised to stop if they experience pain or extreme dis-
comfort, nausea, or dizziness. During the test sessions,
the patients will be continuously monitored with a
digital heart rate monitor (Polar Model) and observed
for adverse reactions/events (see Monitoring Adverse
Events).
Primary endpoint
Functional performance/exercise capacity: 6 minute walk
distance (6MWD) which measures the sub maximal
level of functional and exercise capacity and will be
Table 3 Study assessment schedule
Data Assessment Screening Day -2 Day 0 Day 1 6 weeks 12 weeks 6 months 12 months






6MWD x x x
Aastrand-Rhyming test x x x
Sit to stand test x x x
Biceps arm curl x x x
Patient-reported outcomes x x x x x
Medical chart review x x x x
Weekly assessments
Step counter x x x
MDASI x x x x x
BFI x x x x x




6MWD, 6 minute walk distance; MDASI, M.D. Anderson Symptom Inventory; BFI, Brief Fatigue Inventory; PA Level, Physical Activity Level.
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Society (ATS) guidelines [45]. The ATS Pulmonary
Function Standards Committee developed guidelines for
the 6MWD in clinical settings [46]. The 6MWD was
chosen because it is easy to administer in the outpatient
setting, well tolerated by patients with acute leukemia,
and reflects activities of daily living [47].
Secondary endpoints
Aerobic capacity. A single stage 6 min submaximal exer-
cise test; the Aastrand-Rhyming cycle ergometer test is
used to predict VO2 max values [48]. The test is based
on the linear relationship between VO2 and heart rate.
The patients pulse will be continually monitored using a
wireless heart rate transmitter. Resistance (Watt) is in-
creased to elicit a steady-state heart rate between 125
and 170 beats/min at a speed between 60 and 65 r.p.m.
If after 6 min the HR is above 125 beats/min and stable,
not fluctuating more than 5 beats/min, the test is termi-
nated. VO2 max is determined using a nomogram with
an age and body weight correction factor. VOs max is
stated in ml/kg/min.
Functional performance and muscle strength comprises
three endpoints: (1) Sit to stand test will be performed
as a measure of strength and performance of the lower
extremity muscles. The 30 second sit to stand was devel-
oped as an assessment tool to measure lower body
strength [49]; (2) Biceps Arm Curl measures arm flexorstrength, upper body strength and endurance [50]. The
aim is to perform as many arm curls as possible in 30
seconds; and (3) Measurement of weekly steps and
distance with the step counter: Omron Walking Style
Pro [44].
Clinical outcomes (exploratory endpoints) will include
andropometric characteristics (body mass index (wt(kg)/
ht(m2)), WHO performance status, hospitalization
(days), increased temperature (>38°) (days), elevated C-
reactive protein (days), infections and complications
(type and days), neutropenia and thrombocytopenia
(days), transfusions (platelets and RBC) (number), time
to relapse and survival.
Patient reported outcomes (PRO) in this study are stan-
dardized and validated questionnaires that measure
physical, functional, emotional and social wellbeing,
symptom prevalence, intensity including fatigue and
interference in daily activities. The PRO’s will be admin-
istered and checked for completeness by the study inves-
tigator at baseline, 6 and 12 weeks, and 6 and 12
months; and coded according to the guidelines given in
the questionnaires manuals: (1) The Functional Assess-
ment of Cancer Therapy-Anemia scale (FACT-An) as-
sesses cancer specific Health Related Quality of Life
(HRQOL), the fatigue symptom subscale (An) of the
FACT-An scale and the Trial Outcome Index (TOI)
[51]. (2) The 36-Item Short Form Health Survey (SF-36)
assesses general wellbeing using eight scales measuring
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scales; physical and mental component scales [52]. (3)
The European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire (C30 EORTC
QLQ-C30) assesses Quality of Life (QOL) using a global
health status scale, five functional scales (physical, role,
emotional, cognitive and social functioning) and symp-
tom scales (fatigue, nausea and vomiting, pain, dyspnea,
insomnia, appetite loss, constipation, diarrhea) [53,54].
(4) The Hospital Anxiety and Depression Scale (HADS)
assess psychological wellbeing and is designed to meas-
ure general anxiety and depression in patients with
physical illness [55]. (5) The M.D. Anderson Symptom
Inventory (MDASI) assesses the severity of 13 symptoms
and their impact as evaluated by six interference items
[56]. The MDASI will be additionally administered once
a week prior to the last training session. (6) The Brief
Fatigue Inventory (BFI) assesses fatigue levels and their
impact as evaluated by interference items [57]. The BFI
will also be administered once a week prior to the last
training session.
Physical activity, social network/relations, activation
and ability, and employment (return to work) will be
assessed by the (7) Leisure time physical activity [58], (8)
Physical activity level [59], (9) Multidimensional Scale of
Perceived Social Support (MSPSS) [60], (10) Patient Ac-
tivation Measure (PAM) [61], (11) Self Efficacy Scale
(GSE) [62] and (12) Employment status and ability [63].
A qualitative in-depth face-to-face semistructured inter-
view (n = 25) at 12 weeks carried out by the study investiga-
tor will explore the patients’ perspectives on physical
activity and health, health behavior, and the experiences
and challenges (including barriers) of returning to daily life
regarding issues of health (well-being, vitality/fatigue,
strength, symptom control) and disease (treatment and
management, symptoms, complications), social (network,
family) and employment. Further, we would like to clarify
whether and how the intervention has contributed to the
patients’ experiences of physical, emotional and social
wellbeing and adaptation. Moreover, we aim to describe the
symptom experience from the patients’ perspective, as well
as explore the effect of the intervention on the symptom
burden and symptom interference. A topic and question
guide will be used to aid the focus of the interviews.
Logbook
A ‘monitoring logbook’ will be used to document screen-
ing, adherence to the intervention, unwanted symptoms,
adverse events, and self-reported symptom assessment
and activity levels. All components of the intervention
performed will be recorded on-going including; exercise
mode, frequency, intensity, duration and progression as
well as subjective exercise response (BORG) and heart
rate. Components performed beyond that prescribed inthe intervention program, i.e. weekends or evenings, will
be reported by the patient and then documented. For
each individual component in the programme, adher-
ence to the intervention will be measured by calculating
the percentage of recommended exercise sessions
performed by the patient (number of sessions per-
formed /number of sessions prescribed). The control
group will receive a modified logbook and will be asked
to register activity/exercise mode, frequency and dur-
ation [59], weekly, during the study period as well as
register symptom prevalence, intensity and interference
(weekly) using the symptom assessment scales MDASI
[56] and BFI [57].
Tracking and monitoring adverse events
Patients will be monitored for unwanted symptoms and
adverse events during each intervention session and
throughout the intervention period. The following study
procedures will be incorporated to ensure safety: 1) Prior
to each exercise session, the patient will be monitored
for blood pressure, pulse, temperature and thrombocyte
and hemoglobin levels according to the study’s screening
criteria; 2) During each intervention session, the patients
will be monitored for unwanted symptoms and adverse
events and recorded in the patients study chart; 3)
Symptoms experienced and adverse events will be
discussed with individual patients weekly; 4) Adverse
events will be a steady agenda at the weekly and
monthly study group meetings; and 5) All adverse events
will be reported by completing the hospitals unintended/
accidental event form and will follow the hospitals pro-
cedure for reporting such events.
Ethical considerations
There are presently no rehabilitation programs available
for patients with acute leukemia at the Departments of
Hematology (HH, RH), however upon approval from the
physician, patients may be referred to a municipality re-
habilitation program. Patients in both study arms are
not inhibited from exercising during the study period, as
long as it is in accordance with the departments’ safety
guidelines for daily physical activity and social contact.
Moreover, patients allocated to both the control and
intervention groups will receive usual and optimal care
during the study period.
Potential risks
During the course of the trial, patients will receive two
chemotherapy cycles and consequently experience two
neutropenic periods, each lasting approx. 7–14 days
and during this time patients are especially prone to
experiencing unpleasant symptoms i.e. mucositis, fa-
tigue, and complications i.e. bleeding and infections.
Further, during the trial period, and as a requirement of
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ous catheter (CVC) placed in order to facilitate chemo-
therapy, transfusions and drug delivery. CVC’s have
benefits (minimize extravasation risk and avoid discom-
fort), but are associated with certain risks (infection,
thrombosis). Patients will therefore, be screened and ob-
served (BP, P, T, platelets, hemoglobin, sign of infection
or bleeding) prior to the physical tests and before and
during each exercise session (see Pre-screening and
safety precautions). We will integrate an adverse events
procedure that includes observation, documentation, pa-
tient and study team awareness, discussion and
reporting (see Tracking and monitoring adverse events).
In our previous pilot study, no adverse events or injuries
were observed as a result of the exercise [8], however
two patients experienced aching in the hip area after in-
creasing their walking distance and most patients
reported slight soreness in their muscles the day after
training. No bruising was noted. There were, however,
two incidents during baseline testing of two patients,
one female during the 6MWD tripped and fell to the
floor, and a male patient fell forward and onto the floor
during the sit-to-stand test. Both patients were not in-
jured, and able to carry out the tests at a later time.
Safety measures were then instituted immediately in the
pilot study and these safety measures (using arm rests
during the sit-to-stand test for weakened patients, pa-
tient information regarding wearing appropriate walking
shoes) will continue during the RCT.Approvals and registrations
Study approval is obtained for Herlev Hospital and
Rigshospitalet by the Scientific Ethics Review Committee
of the Capital Region of Denmark (J.no. H-4-2010-046)
and the Danish Data Protection Agency (J.no. 30–0431).
The study is registered at ClinicalTrials.gov Identifier:
NCT01404520.Statistical considerations
Sample size
This randomized controlled trial will include 70 acute
leukemia patients over a recruitment period of 34–36
months. Sample size calculation is based on the primary
endpoint; the 6 min walk distance (6MWD) and the results
from our pilot study (n = 20), where n = 17 completed the
study (15% lost to followup). The pilot study baseline for
6MWD was 450 m and the average change was 56.3 m ef-
fect (SD = 69.2). Assuming that there is no change in the
control group, an inclusion of 70 patients (35 intervention,
35 control) will yield more than 90% power (risk of type 2
error set at 0.10) to detect a difference of this magnitude
between groups using a significance level of 0.05 (risk oftype 1 error set at 0.05). Should 20% be lost to followup
(n = 56), the power will still be larger than 80%.
Analytic plan
Quantitative data
Data will be entered into the OpenClinica database [64]
and statistical analysis will be carried out using Statistical
Analysis Systems (SAS) version 9.2. Procedures for data
entry and audit program have been developed to ensure ac-
curate data entry [65]. Baseline comparisons of demo-
graphic and clinical outcomes will be performed using
independent samples t-tests, and chi-squared tests will be
applied for categorical variables. The primary endpoint will
be reported as an independent samples t-test comparing
change scores in the two randomization groups. The sec-
ondary endpoints (physical and strength tests and PRO
questionnaires) will be reported as means and 95% confi-
dence intervals and medians inter quartile range (IQR) for
continuous variable, while categorical data will be reported
as proportions and compared across randomization groups
using chi-squared tests. The intent-to-treat principle will be
applied and the significance level is set at 0.05. Additional
analyses of 6 and 12 month followup data (PRO question-
naires) and of weekly symptom measurements and physical
activity data will utilize linear mixed models to quantify tra-
jectories. The trials statistician (KBC) will prepare results
without knowledge of assignment to randomization coding.
Qualitative data
Upon consent from the participants, the interviews will
be recorded and transcribed verbatim. Data will be
anonymised and coded using computerized qualitative
data analysis software (NVivo 10) [66]. Thematic analysis
is a qualitative analytic method that identifies, analyzes
and reports themes and patterns within and across cases
[67,68]. This study will apply an inductive, data-driven
approach, which is the process of coding the data with-
out attempting to fit it into a preexisting coding frame.
The six phases of thematic analysis are as follows: (1)
First, the investigator listens to the audio recordings and
reads/re-reads the transcripts to become familiar with
the content of the data. (2) Next, initial codes are gener-
ated from data extracts (sentences or paragraphs), (3)
and from these extracts, the investigator searches for
and reviews the themes, (4) generates a thematic map of
the analysis, (5) defines and labels themes and finally, (6)
identifies common themes. This final phase is the ana-
lysis of selected extracts/themes in relation to the initial
research questions, literature and theory [67,68].
Discussion
PACE-AL will target the special clinical and rehabilita-
tion needs of patients with acute leukemia. Several as-
pects were taken into consideration in the development
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and completion of study requirements. Firstly, the tim-
ing of initiation of the intervention along the treatment
trajectory was considered. Once the diagnosis is
established, patients are immediately hospitalized and in-
duction chemotherapy with curative intent is rapidly ini-
tiated. The patients’ medical situation at this time is
unstable with a particular risk of severe infectious com-
plications [69,70]. Additionally, it can be a challenge for
patients to face the uncertainty of the disease and treat-
ment while experiencing treatment-related symptoms
and side effects. Being that safety is our main concern,
we chose to recruit patients and initiate the intervention
after completion of induction treatment, and once the
patients’ condition is stabilized (CR status). After induc-
tion treatment, patients are typically managed as outpa-
tients for months and it is during this phase in the
treatment trajectory that PACE-AL trial will be initiated.
Secondly, it is reported that patients with hematological
malignancies undergoing intensive chemotherapy have a
low level of ‘naturally occurring’ physical activity,
suggesting that a structured intervention may be neces-
sary in order to promote exercise in this population [71].
However, there are no exercise guidelines available for
patients with acute leukemia. Most exercise trials and re-
habilitation programs institute screening parameters for
participation that require platelet levels of at least 40-50
x 109/l. The units’ transfusion policy (HH, RH) for
thrombocytopenia is platelets < 15 × 109/l, which on a
daily basis and without platelet transfusion would ex-
clude patients in this group from participation in
existing programs. A few trials have safely carried out
moderate physical exercise in patients undergoing inten-
sive chemotherapy with platelet values ≥20 × 109/l
[22,72-74] and >10 × 109/l [26]. PACE-AL will allow ex-
ercise participation with platelet values ≥15 × 109/l. [9]
The safety precautions instituted in this trial include
screening (platelet level, temperature, blood pressure
and signs of infection and bleeding) prior to the physical
tests and intervention, supervision and monitoring dur-
ing the intervention, as well as a procedure for monitor-
ing and reporting intervention-related adverse events.
Thirdly, we considered the treatment setting. We chose
to offer the intervention during the patients waiting time
at the outpatient department to avoid prolonging the
time spent at the hospital. Further, knowing that patients
have difficulty initiating independent exercise during in-
tensive chemotherapy in this setting, we decided to
lengthen the intervention period from 6 weeks in our
pilot study [9] to span over two chemotherapy cycles
(12 weeks). The fourth aspect is the intervention type
and dose. Since patients during outpatient management
are required to visit the unit 3–4 days/week, an exercise
intervention of 3 days/week would be realistic for thepatient. Moreover, we anticipate that patients will be ex-
periencing a relatively high symptom burden and in ef-
fect, do not want to hold the patient longer than
necessary at the department. Therefore, each session will
not exceed 1 hr ± 10 min. We designed the components
of the intervention based on general guidelines sug-
gested by the ACSM [28] and a literature review on
physical activity and hematological cancer survivorship
[22]. The exercise components in this study will include
a combination of aerobic, resistance and relaxation
training of low to moderate intensity 3 days/week á 3–4
hours/week. The walking program with step counter will
be applied as motivation for independent activity. The
step counter will be used as a means of building a bridge
between hospital and daily life to improve the naturally
occurring level of physical activity while at home. The
step counter enables the study team to electronically re-
view the data, and give the patient feedback about their
independent activity level outside the hospital setting.
Knowing that patients are at risk of losing muscle mass
during treatment due to inactivity, prednisolone treat-
ment etc., we will incorporate protein/carbohydrate sup-
plements after each training session to prevent muscle
wasting. Finally, the health counseling and daily
motivation and guidance are important components in
this intervention. Exercise trials for patients with
hematological malignancies are primarily designed as
exercise-only interventions and do not include psycho-
social interventions or report the efforts made to guide
and motivate participants during the individual sessions,
across the intervention study period and long term
[22,25,75].
We chose validated physical and functional capacity
tests that would be feasible in this acute leukemia clin-
ical setting. The tests reflect physical, functional and aer-
obic capacity and upper and lower body muscle
strength. The 6MWD was chosen for the primary end-
point because it reflects activities of daily living, is easy
to administer in the outpatient department and well tol-
erated by patients with acute leukemia undergoing
chemotherapy. The gold standard of maximal oxygen
uptake requires patients to perform a maximal stress
test, however, wearing a mask is uncomfortable for pa-
tients recovering from stomatitis, as reported by Dimeo
[76]. Therefore, oxygen uptake in this study as a second-
ary endpoint will be estimated by a submaximal cycle
test, requiring a work intensity that will be realistic for
weakened patients at all test points [48].
Summary
Inactive periods during treatment for acute leukemia are
frequently related to fatigue and depression, and can
lead to reduced cardio respiratory capacity, as well as
impaired muscular function, affecting the ability to carry
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treatment and care pathway, appropriate exercise guide-
lines and rehabilitation programs for patients undergo-
ing treatment for acute leukemia need to be established
to ease the transition from illness to the resumption of
everyday activities, e.g. job/school. PACE-AL trial will
study the effect of a 12 week supervised and structured
exercise and health promotion counseling intervention
on physical and functional capacity, symptom burden
and symptom interference with daily activities, quality of
life, psychosocial and clinical outcomes in patients with
acute leukemia undergoing intensive chemotherapy dur-
ing outpatient management.
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